144702-27-2

Usage

Uses

Used in Pharmaceutical Industry:
Propyl[2,6'-bi-1H-benzimidazol]-1'-yl]methyl]is used as an active pharmaceutical ingredient for the development of novel drugs targeting various medical conditions. Its unique molecular structure allows for specific interactions with biological targets, potentially leading to the development of more effective treatments.
Used in Chemical Synthesis:
In the field of chemical synthesis, propyl[2,6'-bi-1H-benzimidazol]-1'-yl]methyl]serves as a key intermediate or building block in the synthesis of more complex molecules. Its versatile structure can be further modified or functionalized to create a wide range of compounds with diverse applications.
Used in Material Science:
Propyl[2,6'-bi-1H-benzimidazol]-1'-yl]methyl]can be utilized in the development of advanced materials with specific properties, such as improved stability, enhanced mechanical strength, or tailored optical characteristics. Its incorporation into polymers or other materials can lead to the creation of novel products with unique performance characteristics.
Used in Research and Development:
Due to its unique structure and potential applications, propyl[2,6'-bi-1H-benzimidazol]-1'-yl]methyl]is also used in research and development settings. Scientists and researchers can explore its properties and potential applications in various fields, leading to the discovery of new uses and advancements in technology.

Upstream product

• 114772-54-2 4'-(bromomethyl)-1,1'-biphenyl-2-carbonitrile 
• 152628-02-9 2-n-propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)benzimidazole 
• 1098100-87-8 2-cyano-4'-[2-n-propyl-4-methyl-6-carboxylate-benzimidazole-1-ylmethyl]biphenyl 
• 25148-68-9 N-methylbenzene-1,2-diamine dihydrochloride 
• 860787-42-4 4-amino-3-bromo-5-methylbenzoic acid 
• 3113-71-1 3-methyl-4-nitrobenzoic acid 
• 4760-34-3 N-methyl-1,2-phenylenediamine 
• 152628-01-8 4-butyrylamino-3-methyl-5-nitro-benzoic acid methyl ester 
• 675882-71-0 3-methyl-4-butyrylamino-5-aminobenzoic acid methyl ester 
• 152628-00-7 4-methyl-2-propyl-1H-benzimidazole-6-carboxylic acid methyl ester 
• 1098100-86-7 2-cyano-4'-[2-n-propyl-4-methyl-6-methylcarboxylate-benzimidazole-1-ylmethyl]biphenyl 
• 136304-93-3 4-(2'-cyanophenyl)benzyl chloride 
• 114772-53-1 2-Cyano-4'-methylbiphenyl 
• 1098100-91-4 4'-((N,7-dimethyl-N-(2-aminophenyl)-2-propyl-3H-benzo[d]imidazole-5-carboxamide-3-yI)-methyl)-biphenyl-2-nitrile 

Downstream Products

• 144701-48-4 telmisatran 
• 1100995-38-7 4'-{[2-n-propyl-4-methyl-6-(1-methylbenzoimidazol-2-yl)benzoimidazol-1-yl]methyl}-2-(1H-imidazoline-2-yl)biphenyl 
• 960356-45-0 telmisartan meglumine salt 
• 960356-41-6 telmisartan choline salt 
• 960356-49-4 telmisartan tris-(hydroxymethyl)amine salt 
• 960356-46-1 telmisartan ethanolamine salt 
• 960356-48-3 telmisartan diethylamine salt 
• 862286-67-7 telmisartan tert-butylamine salt 
• 960356-44-9 4'-[[2-n-propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid ammonium salt 
• 915124-86-6 4’-((1,7′-dimethyl-2′-propyl-1H,3′H-[2,5′-bibenzo[d]imidazol]-3′-yl)methyl)-[1,1′-biphenyl]-2-carboxamide 
• 515815-48-2 tert-butyl-4'-[[2-n-propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylate hydrochloride 

Relevant academic research and scientific papers

Compound based on benzimidazole substituted halogenated phenyl n-butylamidine and preparation method of compound

The invention relates to a compound based on benzimidazole substituted halogenated phenyl n-butylamidine as shown in a formula II and a preparation method thereof. According to the method disclosed by the invention, nitrification and polyphosphoric acid cyclization reactions are avoided, and the generation of a large amount of waste acid reaction liquid is avoided from the source.

An improved synthesis of telmisartan: Via the copper-catalyzed cyclization of o -haloarylamidines

A concise synthetic route was designed for making telmisartan. The key bis-benzimidazole structure was constructed via the copper-catalyzed cyclization of o-haloarylamidines. By adopting this approach, telmisartan was obtained in a 7-step overall yield of 54% starting from commercially available 3-methyl-4-nitrobenzoic acid, and the use of HNO3/H2SO4 for nitration and polyphosphoric acid (PPA) for cyclization in the reported literatures were avoided.

Method for preparing telmisartan and intermediates thereof

Disclosed is a telmisartan preparation method, characterized in that: 2-n-propyl-4-methyl-6-(1-methyl benzimidazole-2-yl) benzimidazole (compound I) and 4'-halomethyl diphenyl-2-substituted compound (compound II) conduct a nucleophilic substitution reaction to obtain a compound III; when R is COOH, the compound III is telmisartan; and when R is COOR' or CN, the compound III can be hydrolyzed to obtain telmisartan.

ONE POT PROCESS FOR THE PREPARATION OF TELMISARTAN

A process for the preparation of bromine free telmisartan in one pot starting from 2-cyano-4′-methyl biphenyl. The process uses raw materials which are readily available to yield telmisartan, its salts and derivatives thereof, which are bromine free and potentially less genotoxic, since there is no bromine atom in any of the raw materials. The process can also be carried out in multiple steps by isolation of the intermediate compounds. The intermediate compound 4-chloromethyl-2′-cyanobiphenyl can also be used for the preparation of irbesartan and other sartans.

ONE POT PROCESS FOR THE PREPARATION OF TELMISARTAN

A process for the preparation of bromine free telmisartan in one pot starting from 2-cyano-4'- methyl biphenyl, a compound of the Formula (1). The compound of the Formula (1) is chlorinated to give 4-chloromethyl-2' -cyanobiphenyl, the compound of the Formula (2). The reaction of the compound of the Formula (2), with 2-n-propyl-4-methyl-6-(1'- methylbenzimidazol-2'-yl) benzimidazole, a compound of the Formula (3) yields the compound 2-cyano-4'-[2"-n-propyl-4"-methyl-6"-(1'"-methylbenzimidazol-2"'- yl) benzimidazol-1"- ylmethyl] biphenyl, a compound of the Formula (4) which on hydrolysis of the cyano group yields telmisartan a compound of the Formula (5).

A NEW PROCESS FOR THE PREPARATION OF PURE TELMISARTAN

This invention provides a process for preparing pure telmisartan by condensing 2- n-propyl-4-methyl-6-(r-methylbenzimidazol-2'-yl) benzimidazole (I) with a compound of formula (II) to obtain the compound 2-cyano-4'-[2"-n-propyl-4"-methyl- 6"-(l"'-methylbenzimidazol-2"'-yl)benzimidazol-l"-ylmethyl] biphenyl (III), and subsequently hydrolyzing the isolated nitrile function group to obtain the telmisartan.

PROCESS FOR THE PREPARATION OF TELMISARTAN

The invention relates to processes for preparing telmisartan or a pharmaceutically acceptable salt thereof as well as to a process for preparing a telmisartan cyano intermediate. Moreover, the invention relates to a multilayer pharmaceutical tablet comprising (a) at least one first tablet layer comprising 1 to 50 wt. -% telmisartan or a pharmaceutically acceptable salt thereof by weight of the first tablet layer and (b) at least one second tablet layer comprising 1 to 50 wt.-% of a diuretic and 50 to 99 wt.-% of at least one filler by weight of the second tablet layer, wherein the combined weight of the diuretic and the at least one filler is at least 87 wt.-% by weight of the second tablet layer. The invention also relates to a process for the preparation of a multilayer pharmaceutical tablet.

NOVEL INTERMEDIATES AND METHOD FOR SYNTHESIS OF 4'-[(1,4'-DIMETHYL-2'-PROPYL-[2,6'- BI-1HBENZIMIDAZOL]-L-YL)METHYL]-1,1-BIPHENYL]-2-CARBOXYLIC ACID.

Disclosed herein is a method for synthesis of 4'-[(1,4'-dimethyl-2'-propyl-[2,6'-bi- 1H]benzimidazol]-l-yl)methyl]-[1,1-biphenyl]-2-carboxylic acid or its derivatives, and novel intermediate compounds useful in the synthesis.

PROCESS FOR PREPARING TELMISARTAN

Novel processes for preparing a telmisaitan nitrile intermediate (4'-[{2-n-propyl-4- methyI-6-f l-methyJbenzimidazol-2-yl)-benzimidazol- l -yl)-methyl]-biphenyl-2-nitrile) and further converting it to telmisaitan and/or salts thereof are disclosed.

Synthesis and biological activities of novel nonpeptide angiotensin II receptor antagonists based on benzimidazole derivatives bearing a heterocyclic ring

A series of benzimidazole derivatives bearing a heterocyclic ring imidazole (1), 5-chloroimidazole (2), 1,2,4-triazol (3), and imidazoline (4) were synthesized and evaluated for angiotensin II antagonistic activities. The synthetic compounds 1-4 were biologically evaluated in vitro using an AT1 receptor binding assay, where compounds 1 and 3 provided weak binding affinity, compound 2 showed moderate binding affinity, and compound 4 showed good binding affinity. Moreover, compound 4 was found to be almost equipotent with telmisartan in vivo biological evaluation study.